USER ID: 
 PASSWORD: 
Course Overview

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the debate over whether levodopa is potentially neurotoxic to remaining dopaminergic neurons in Parkinson’s disease
  • Recognize the range of motor complications caused by levodopa and the mechanism responsible for their development
  • Recognize the therapeutic usefulness of levodopa in the treatment of Parkinson’s disease


Agenda/Faculty Affliations and Credentials:

Opening Remarks and Program Overview
Peter Jenner, PhD, DSc
Co-chair
King's College London
London, United Kingdom

Levadopa: Is it Toxic?
Stanley Fahn, MD
Neurology Institute
New York, NY

Levodopa: How Does it Cause Motor Complications?
José A. Obeso, MD, PhD
University of Navarra
Pamplona, Spain

A Rationale for the Early Use of Carbidopa/Levodopa/Entacapone
Fabrizio Stocchi, MD, PhD
Co-chair
Professor
IRCCS Neuromed
Rome, Italy
(c) 2006 The Movement Disorder Society & The Center for Advanced Medical Education. All rights reserved. Privacy Statement